UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Ekso Bionics Holdings,
Inc.
(Exact name of
registrant as specified in its charter)
Nevada
(State or other jurisdiction of incorporation or
organization)
|
99-0367049
(I.R.S. Employer Identification No.)
|
|
|
1414 Harbour Way, Suite 1201
Richmond, California
(Address of Principal Executive Offices)
|
94804
(Zip Code)
|
Amended and Restated 2014 Equity Incentive Plan
(Full
Title of the Plan)
Jack Peurach, CEO
Ekso Bionics Holdings, Inc.
1414 Harbour Way, Suite 1201
Richmond, CA 94804
(510) 984-1761
(Name, address and telephone number,
including area code, of agent for service)
Copy to:
Alfredo B. D. Silva, Esq.
Morrison & Foerster, LLP
425 Market Street
San Francisco, CA 94105
(415) 268-7000
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, a
smaller reporting company, or an emerging growth company. See the
definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule
12b-2 of the Exchange Act.
Large accelerated filer |
¨ |
Accelerated filer |
¨ |
Non-accelerated filer |
x |
Smaller reporting company |
x |
|
|
Emerging growth company |
¨ |
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of Securities
Act. ¨
CALCULATION OF REGISTRATION FEE
Title of Securities to be Registered |
|
Amount
to be
Registered (1) |
|
|
Proposed
Maximum
Offering
Price Per
Share (2) |
|
|
Proposed
Maximum
Aggregate
Offering
Price (2) |
|
|
Amount of
Registration
Fee (2) |
|
Common stock, $0.001 par value per
share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
—Amended
and Restated 2014 Equity Incentive Plan |
|
|
800,000 |
|
|
$ |
8.11 |
|
|
$ |
6,488,000 |
|
|
$ |
707.85 |
|
TOTAL: |
|
|
800,000 |
|
|
|
|
|
|
$ |
6,488,000 |
|
|
$ |
707.85 |
|
(1) |
Pursuant to Rule 416(a) of the
Securities Act of 1933, as amended (the “Securities Act”), this
Registration Statement shall also cover an indeterminate number of
additional shares of the registrant’s common stock that become
issuable under the Amended and Restated 2014 Equity Incentive Plan,
as amended (the “Plan”), by reason of any stock dividend, stock
split, recapitalization or other similar transaction effected
without receipt of consideration that increases the number of the
Registrant’s outstanding shares of common stock. |
|
|
(2) |
Estimated in accordance with Rules
457(c) and (h) of the Securities Act solely for the purpose of
calculating the registration fee on the basis of $8.11, the average
of the high ($8.33) and low ($7.89) prices of the Registrant’s
common stock as reported on the Nasdaq Capital Market on February
24, 2021. |
EXPLANATORY NOTE; INCORPORATION BY REFERENCE OF CONTENTS OF
REGISTRATION STATEMENTS ON FORMS S-8 (NO. 333-232512; NO.
333-226037; NO. 333-220808; NO. 333-207131; NO. 333-198357)
This Registration Statement registers additional securities of the
same class as other securities for which registration statements
filed on Forms S-8 relating to Ekso Bionics Holdings, Inc.’s
Amended and Restated 2014 Equity Incentive Plan (the “Plan”) are
already effective. Pursuant to Instruction E to Form S-8, we
incorporate by reference into this Registration Statement the
contents of (a) the registration statement on
Form S-8 (File No. 333-198357) that we
filed with the Securities and Exchange Commission (the “SEC”) on
August 26, 2014 relating to the registration of 137,238
shares of our common stock authorized for issuance under the Plan
(taking into account a 1-for-7 reverse stock split on May 4, 2016
and a 1-for-15 reverse stock split on March 24, 2020), (b) the
registration statement on
Form S-8 (File No. 333-207131) that we
filed with the SEC on September 25, 2015, relating to
the registration of 110,380 shares of our common stock authorized
for issuance under the Plan (taking into account a 1-for-7 reverse
stock split on May 4, 2016 and a 1-for-15 reverse stock split on
March 24, 2020), (c) the registration statement on
Form S-8 (File No. 333-220808) that we
filed with the SEC on October 4, 2017, relating to the
registration of 66,666 shares of our common stock authorized for
issuance under the Plan (taking into account a 1-for-15 reverse
stock split on March 24, 2020), (d) the registration statement on
Form S-8 (File No. 333-226037) that we
filed with the SEC on July 2, 2018, relating to the
registration of 293,333 shares of our common stock authorized for
issuance under the Plan (taking into account a 1-for-15 reverse
stock split on March 24, 2020), (e) the registration statement on
Form S-8 (File No. 333-232512) that we
filed with the SEC on July 2, 2019, relating to the
registration of 233,333 shares of our common stock authorized for
issuance under the Plan (taking into account a 1-for-15 reverse
stock split on March 24, 2020), and (f) the registration statement
on
Form S-8 (File No. 333-237527) that we
filed with the SEC on April 1, 2020, relating to the registration of 333,334
shares of our common stock authorized under the Plan, in each case,
in their entirety and including exhibits thereto. This Registration
Statement provides for the registration of an additional 800,000
shares of common stock to be issued under the Plan. These 800,000
shares represent an increase in the number of shares of common
stock reserved for issuance under the Plan, which increase was
approved by the stockholders on December 29, 2020. As a result of
the foregoing, the total number of shares of common stock
registered for offer and sale under the Plan is now 1,974,284
(taking into account a 1-for-7 reverse stock split on May 4, 2016
and a 1-for-15 reverse stock split on March 24, 2020).
PART II
INFORMATION REQUIRED IN THE
REGISTRATION STATEMENT
Item 3. |
Incorporation of Documents by
Reference. |
The registrant hereby incorporates by reference into this
Registration Statement the following documents previously filed
with the Securities and Exchange Commission:
(a) The registrant’s Annual Report on Form 10-K for the fiscal year
ended December 31, 2020, filed with the SEC on February 25,
2021;
(b) The registrant’s Current Reports on Form 8-K, filed with the
SEC on January 13, 2021 (as to Item 8.01
only), February 8, 2021 and February 11, 2021; and
(c) The description of the registrant’s common stock contained in
the Registrant’s Registration Statement on
Form 8-A (File No. 001-37854) filed
with the SEC on August 8, 2016, pursuant to Section
12(b) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), including any amendment or report filed for the
purpose of updating such description.
All documents filed by the registrant pursuant to Sections 13(a),
13(c), 14 and 15(d) of the Exchange Act on or after the date of
this Registration Statement and prior to the filing of a
post-effective amendment to this Registration Statement that
indicates that all securities offered have been sold or that
deregisters all securities then remaining unsold shall be deemed to
be incorporated by reference in this Registration Statement and to
be part hereof from the date of filing of such documents;
provided, however, that documents or information
deemed to have been furnished and not filed in accordance with the
rules of the SEC shall not be deemed incorporated by reference into
this Registration Statement. Any statement contained in a document
incorporated or deemed to be incorporated by reference herein shall
be deemed to be modified or superseded for purposes of this
Registration Statement to the extent that a statement contained
herein or in any subsequently filed document which also is deemed
to be incorporated by reference herein modifies or supersedes such
statement. Any such statement so modified or superseded shall not
be deemed, except as so modified or superseded, to constitute a
part of this Registration Statement.
Exhibit No.
|
|
Description of Exhibit
|
4.1 |
|
Articles of
Incorporation of the Registrant (incorporated by reference from
Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K filed on
March 19, 2015) |
4.2 |
|
By-Laws of the
Registrant (incorporated by reference from Exhibit 3.4 to the
Registrant’s Current Report on Form 8-K filed on January 23,
2014) |
4.3 |
|
Certificate of Change of
Ekso Bionics Holdings, Inc. effective May 4, 2016 (incorporated by
reference from Exhibit 3.1 to the Registrant’s Current Report on
Form 8-K filed on May 5, 2016) |
4.4 |
|
Certificate of Amendment
of Certificate of Incorporation of Ekso Bionics Holdings, Inc.
(incorporated by reference from Exhibit 3.1 to the Registrant’s
Current Report on Form 8-K filed on December 27,
2017) |
4.5 |
|
Certificate of Amendment to Articles of
Incorporation of the Registrant, filed on March 24, 2020, effective
as of March 24, 2020 (incorporated by reference from Exhibit 3.1
to the Registrant’s Current Report on Form 8-K filed on March 24,
2020) |
4.6 |
|
Form of specimen
certificate (incorporated by reference from Exhibit 4.4 to the
Registrant’s Registration Statement on Form S-3 filed on June 23,
2015) |
5.1* |
|
Opinion of
Snell & Wilmer L.L.P. |
23.1* |
|
Consent of
Snell & Wilmer L.L.P. (included in Exhibit 5.1) |
23.2* |
|
Consent of
OUM & Co, LLP |
24.1* |
|
Power of Attorney (included in the signature page
to this Registration Statement) |
99.1 |
|
The
Registrant’s Amended and Restated 2014 Equity Incentive Plan
(incorporated by reference from Appendix A to Registrant’s
Definitive Proxy Statement on Schedule 14A, filed on November 12,
2020) |
|
|
|
* Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
registrant certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form S-8 and has
duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of
Richmond, State of California, on February 25, 2021.
|
EKSO BIONICS HOLDINGS,
INC. |
|
|
|
|
By: |
/s/ John F. Glenn |
|
|
John F. Glenn |
|
|
Chief Financial Officer |
|
|
(principal financial and accounting
officer) |
SIGNATURES AND POWER OF ATTORNEY
We, the undersigned officers and directors of Ekso Bionics
Holdings, Inc., hereby severally constitute and appoint Jack
Peurach and John F. Glenn, and each of them singly (with full power
to each of them to act alone), our true and lawful
attorneys-in-fact and agents, with full power of substitution and
resubstitution in each of them for her or him and in her or his
name, place and stead, and in any and all capacities, to sign any
and all amendments (including post-effective amendments) to this
registration statement (or any other registration statement for the
same offering that is to be effective upon filing pursuant to Rule
462(b) under the Securities Act of 1933), and to file the same,
with all exhibits thereto and other documents in connection
therewith, with the Securities and Exchange Commission, granting
unto said attorneys-in-fact and agents, and each of them, full
power and authority to do and perform each and every act and thing
requisite or necessary to be done in and about the premises, as
full to all intents and purposes as she or he might or could do in
person, hereby ratifying and confirming all that said
attorneys-in-fact and agents or any of them or their or her or his
substitute or substitutes may lawfully do or cause to be done by
virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as
amended, this Registration Statement has been signed by the
following persons in the capacities and on the dates indicated.
Signatures
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Steven Sherman
Steven Sherman
|
|
Director and Executive
Chairman |
|
February 25, 2021 |
|
|
|
|
|
/s/ Jack Peurach
Jack Peurach
|
|
Director and Chief Executive
Officer
(principal executive officer) |
|
February 25, 2021 |
|
|
|
|
|
/s/ John F. Glenn
John F. Glenn
|
|
Chief Financial Officer
(principal financial and accounting officer) |
|
February 25, 2021 |
|
|
|
|
|
/s/ Charles Li
Charles Li, Ph.D.
|
|
Director |
|
February 25, 2021 |
|
|
|
|
|
/s/ Ted Wang
Ted Wang, Ph.D.
|
|
Director |
|
February 25, 2021 |
|
|
|
|
|
/s/ Mary Ann Cloyd
Mary Ann Cloyd
|
|
Director |
|
February 25, 2021 |
|
|
|
|
|
/s/ Rhonda A. Wallen
Rhonda A. Wallen
|
|
Director |
|
February 25, 2021 |
|
|
|
|
|
/s/ Stanley Stern
Stanley Stern
|
|
Director |
|
February 25, 2021 |